JN
Johnson & Johnson
JNJ.DE · XETRA
231.15 € -1.87% (-4.40 €)
1M +2.38%
Market Cap $647.8B
P/E Ratio 30.81x
Div. Yield 2.44%
ROE 25.72%
Bulios Fair Price
169.31 €
26.8% downside
Current Price
231.15 €
Undervalued Fair Value Overvalued
According to Bulios Fair Price, JNJ.DE is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Strong
8/9Valuation
35 /100
Fair P/E 30.81x
EV/EBITDA 20.09x
P/S 6.62x
Growth
47 /100
Stable EPS growth 17.90%
Rev. growth 0.26%
FCF growth 3.97%
Profitability
100 /100
Strong Gross margin 72.78%
Net margin 21.48%
Op. margin 26.99%
Quality
80 /100
Excellent ROIC 13.97%
ROE 25.72%
ROA 10.46%
Debt
81 /100
Low Debt/Equity 0.58x
Current ratio 1.09x
Int. coverage 27.88x
Stability
46 /100
Moderate Beta 0.24x
Rev. volatility 8.98%
EPS volatility 89.79%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about JNJ.DE
Online
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Joaquin Duato
Employees
138,200
Headquarters
New Brunswick
Upcoming events
13 OCT
Earnings
Upcoming earnings report